Tags

Type your tag names separated by a space and hit enter

Acute drug treatment of migraine attack.
Neurol Sci. 2004 Oct; 25 Suppl 3:S113-8.NS

Abstract

The availability of an effective drug for attack treatment is a main need of migraine patients. Symptomatic therapy of migraine now includes three main classes of drugs: ergot alkaloids, nonsteroidal antiinflammatory drugs (NSAIDs) and triptans. Clinical randomised placebo-controlled trials affirmed the efficacy and tolerability of these drugs, when used at the recommended doses and in the absence of contraindications. The efficacy data from comparative trials showed a trend in favour of triptans vs. ergot alkaloids, but failed to show significant differences between triptans and NSAIDs. However, clinical practice experience of most headache clinicians suggests that triptans provide superior efficacy in comparison with nonspecific agents, mainly in that they better satisfy migraine patient expectations. In fact, these selective specific antimigraine drugs are an advance in acute migraine treatment.

Authors+Show Affiliations

A.O.U. G. Martino, Clinica Neurologica I, Via C. Valeria, Contesse, I-98124 Messina, Italy. mcnarbone@yahoo.itNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

15549517

Citation

Narbone, M C., et al. "Acute Drug Treatment of Migraine Attack." Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, vol. 25 Suppl 3, 2004, pp. S113-8.
Narbone MC, Abbate M, Gangemi S. Acute drug treatment of migraine attack. Neurol Sci. 2004;25 Suppl 3:S113-8.
Narbone, M. C., Abbate, M., & Gangemi, S. (2004). Acute drug treatment of migraine attack. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 25 Suppl 3, S113-8.
Narbone MC, Abbate M, Gangemi S. Acute Drug Treatment of Migraine Attack. Neurol Sci. 2004;25 Suppl 3:S113-8. PubMed PMID: 15549517.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Acute drug treatment of migraine attack. AU - Narbone,M C, AU - Abbate,M, AU - Gangemi,S, PY - 2004/11/19/pubmed PY - 2005/1/6/medline PY - 2004/11/19/entrez SP - S113 EP - 8 JF - Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology JO - Neurol Sci VL - 25 Suppl 3 N2 - The availability of an effective drug for attack treatment is a main need of migraine patients. Symptomatic therapy of migraine now includes three main classes of drugs: ergot alkaloids, nonsteroidal antiinflammatory drugs (NSAIDs) and triptans. Clinical randomised placebo-controlled trials affirmed the efficacy and tolerability of these drugs, when used at the recommended doses and in the absence of contraindications. The efficacy data from comparative trials showed a trend in favour of triptans vs. ergot alkaloids, but failed to show significant differences between triptans and NSAIDs. However, clinical practice experience of most headache clinicians suggests that triptans provide superior efficacy in comparison with nonspecific agents, mainly in that they better satisfy migraine patient expectations. In fact, these selective specific antimigraine drugs are an advance in acute migraine treatment. SN - 1590-1874 UR - https://www.unboundmedicine.com/medline/citation/15549517/Acute_drug_treatment_of_migraine_attack_ L2 - https://link.springer.com/10.1007/s10072-004-0266-8 DB - PRIME DP - Unbound Medicine ER -